615 related articles for article (PubMed ID: 27138902)
1. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
3. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
5. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
De Menis E; Visentin A; Billeci D; Tramontin P; Agostini S; Marton E; Conte N
J Endocrinol Invest; 2001 Feb; 24(2):92-7. PubMed ID: 11263478
[TBL] [Abstract][Full Text] [Related]
6. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
7. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
10. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
11. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
[TBL] [Abstract][Full Text] [Related]
12. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
13. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
[TBL] [Abstract][Full Text] [Related]
14. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
15. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
16. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
17. Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
Lambert K; Rees K; Seed PT; Dhanjal MK; Knight M; McCance DR; Williamson C
Obstet Gynecol; 2017 Jan; 129(1):185-194. PubMed ID: 27926659
[TBL] [Abstract][Full Text] [Related]
18. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.
Shimon I; Hirsch D; Tsvetov G; Robenshtok E; Akirov A; Fraenkel M; Eizenberg Y; Herzberg D; Barzilay-Yoseph L; Livner A; Friedrich I; Manisterski Y; Ishay A; Yoel U; Masri H
Endocrine; 2019 Sep; 65(3):656-661. PubMed ID: 31154607
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
